Are we really effective?
Are we really effective? What you will find in this Annual Review, I hope, is a resounding ‘yes’.
You’ll find hard facts and figures about what we’re achieving with charitable grants, donations from individuals, and support from companies. And you’ll see what they mean in real life for men with prostate cancer and their families.
Our expertise in supporting men through the distress of diagnosis, and providing clear information about different treatments, for example, has been recognised by Guy’s and St Thomas’ NHS Foundation Trust, which has invited us to create a shared specialist prostate cancer nurse post. It has also been tapped into by many general cancer charities, leading to referrals to our Helpline.
The Prostate Cancer Charity is also striving to help the young men who will develop prostate cancer in the future. You can read how our Real Man Campaign – to make people aware of prostate cancer symptoms – succeeded in having a much greater impact than you might expect possible from our limited resources.
This magnifying effect is a feature of The Prostate Cancer Charity. We believe fiercely that powering a collaborative effort is the key to tackling prostate cancer’s major challenges. Together we are achieving progress on a scale that none of us could manage alone. Will you join us?
John Neate, Chief Executive
john.neate@prostate-cancer.org.uk
One in 11 men in the UK will be diagnosed with prostate cancer. It is the men’s health issue. The Prostate Cancer Charity:
• funds medical research, peer-reviewed by internationally-renowned scientists
• provides information for men and their families about symptoms, diagnosis and treatment options
• offers support through our Helpline, specialist nurses and a nationwide network of men who have had prostate cancer
• raises awareness among men and among politicians and policy-makers so that prostate cancer climbs the health agenda.
We were able to do this in 2005/06 thanks to the individuals, trusts and companies who generously gave or raised over £3.7 million.